Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003562
Status:
UNKNOWN
Last Update Posted:
2013-12-04
First Post:
1999-11-01
Brief Title:
Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Sponsor:
Hope Cancer Institute Inc
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin
Status:
UNKNOWN
Status Verified Date:
2001-03
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining more than one drug may kill more tumor cells
PURPOSE Phase II trial to study the effectiveness of combining docetaxel and carboplatin in treating patients who have stage IIIB or stage IV non-small cell lung cancer
PURPOSE Phase II trial to study the effectiveness of combining docetaxel and carboplatin in treating patients who have stage IIIB or stage IV non-small cell lung cancer
Detailed Description:
OBJECTIVES I Determine the effectiveness of low dose docetaxel and carboplatin by response rate response duration and time to progression in patients with stage IIIB or IV non-small cell lung cancer II Determine the side effects and toxicity profile of docetaxel when given in combination with carboplatin in these patients
OUTLINE This is open label study Patients receive docetaxel IV over 1 hour followed by carboplatin IV over 30 minutes once a week for 4 weeks Patients receive at least 2 courses 8 weeks of treatment Courses are further repeated in the absence of unacceptable toxicity and disease progression
PROJECTED ACCRUAL There will be 20-38 patients accrued into this study
OUTLINE This is open label study Patients receive docetaxel IV over 1 hour followed by carboplatin IV over 30 minutes once a week for 4 weeks Patients receive at least 2 courses 8 weeks of treatment Courses are further repeated in the absence of unacceptable toxicity and disease progression
PROJECTED ACCRUAL There will be 20-38 patients accrued into this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HCRN-007 | None | None | None |
| NCI-V98-1469 | None | None | None |